Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
Ainos (NASDAQ:AIMD) has secured exclusive licensing rights for 28 multi-regional patent assets from strategic shareholder Taiwan Carbon Nano Technology (TCNT). The patents cover AI Nose gas sensing technology and a breakthrough nitrogen-oxygen separation technology for medical applications. The new separation technology achieves over 99% purity while using one-third of the energy compared to conventional methods, offering significant cost reduction and environmental benefits.
The patent portfolio spans multiple regions including China, Japan, Korea, Taiwan, Germany, the EU, and the US. The agreement grants Ainos exclusive sales rights for the medical-grade nitrogen-oxygen separation technology, positioning the company for expansion in the advanced medical equipment market.
Ainos (NASDAQ:AIMD) ha ottenuto i diritti di licenza esclusivi per 28 asset di brevetto multi-regionali da parte dell'azionista strategico Taiwan Carbon Nano Technology (TCNT). I brevetti riguardano la tecnologia di rilevamento dei gas AI Nose e una tecnologia innovativa di separazione dell'azoto e dell'ossigeno per applicazioni mediche. La nuova tecnologia di separazione raggiunge oltre il 99% di purezza utilizzando un terzo dell'energia rispetto ai metodi convenzionali, offrendo significativi risparmi sui costi e benefici ambientali.
Il portafoglio di brevetti copre più regioni, tra cui Cina, Giappone, Corea, Taiwan, Germania, UE e Stati Uniti. L'accordo concede ad Ainos diritti di vendita esclusivi per la tecnologia di separazione azoto-ossigeno di grado medico, posizionando l'azienda per un'espansione nel mercato dei dispositivi medici avanzati.
Ainos (NASDAQ:AIMD) ha obtenido los derechos de licencia exclusivos para 28 activos de patentes multi-regionales de su accionista estratégico Taiwan Carbon Nano Technology (TCNT). Las patentes abarcan la tecnología de detección de gases AI Nose y una innovadora tecnología de separación de nitrógeno y oxígeno para aplicaciones médicas. La nueva tecnología de separación logra más del 99% de pureza utilizando un tercio de la energía en comparación con los métodos convencionales, lo que ofrece una reducción significativa de costos y beneficios ambientales.
El portafolio de patentes abarca múltiples regiones, incluyendo China, Japón, Corea, Taiwán, Alemania, la UE y los EE. UU. El acuerdo otorga a Ainos derechos exclusivos de venta para la tecnología de separación de nitrógeno y oxígeno de grado médico, posicionando a la empresa para una expansión en el mercado de equipos médicos avanzados.
Ainos (NASDAQ:AIMD)는 전략적 주주인 대만 탄소 나노 기술(TCNT)으로부터 28개의 다중 지역 특허 자산에 대한 독점 라이선스 권리를 확보했습니다. 이 특허는 AI Nose 가스 감지 기술과 의료 용도를 위한 혁신적인 질소-산소 분리 기술을 포함합니다. 새로운 분리 기술은 기존 방법에 비해 에너지를 3분의 1만 사용하면서 99% 이상의 순도를 달성하며, 이는 비용 절감과 환경적 이점을 제공합니다.
특허 포트폴리오는 중국, 일본, 한국, 대만, 독일, EU 및 미국을 포함한 여러 지역에 걸쳐 있습니다. 이번 계약은 Ainos에게 의료 등급의 질소-산소 분리 기술에 대한 독점 판매 권리를 부여하여, 첨단 의료 장비 시장에서의 확장을 위한 기반을 마련합니다.
Ainos (NASDAQ:AIMD) a obtenu les droits de licence exclusifs pour 28 actifs de brevets multi-régionaux de l'actionnaire stratégique Taiwan Carbon Nano Technology (TCNT). Les brevets couvrent la technologie de détection des gaz AI Nose et une technologie révolutionnaire de séparation azote-oxygène pour des applications médicales. La nouvelle technologie de séparation atteint plus de 99 % de pureté tout en utilisant un tiers de l'énergie par rapport aux méthodes conventionnelles, offrant ainsi des réductions de coûts significatives et des avantages environnementaux.
Le portefeuille de brevets s'étend sur plusieurs régions, y compris la Chine, le Japon, la Corée, Taïwan, l'Allemagne, l'UE et les États-Unis. L'accord accorde à Ainos des droits de vente exclusifs pour la technologie de séparation azote-oxygène de qualité médicale, positionnant l'entreprise pour une expansion sur le marché des équipements médicaux avancés.
Ainos (NASDAQ:AIMD) hat die exklusiven Lizenzrechte für 28 multi-regionale Patentwerte von dem strategischen Anteilseigner Taiwan Carbon Nano Technology (TCNT) gesichert. Die Patente umfassen die AI Nose Gassensortechnologie sowie eine bahnbrechende Stickstoff-Sauerstoff-Trenntechnologie für medizinische Anwendungen. Die neue Trennungstechnologie erreicht eine Reinheit von über 99% bei einem Energieverbrauch von nur einem Drittel im Vergleich zu herkömmlichen Methoden, was eine signifikante Kostenreduzierung und umweltfreundliche Vorteile bietet.
Das Patentportfolio umfasst mehrere Regionen, darunter China, Japan, Korea, Taiwan, Deutschland, die EU und die USA. Die Vereinbarung gewährt Ainos exklusive Verkaufsrechte für die medizinische Stickstoff-Sauerstoff-Trenntechnologie und positioniert das Unternehmen für eine Expansion im Markt für fortschrittliche medizinische Geräte.
- Secured exclusive licensing rights for 28 multi-regional patents
- New nitrogen-oxygen separation technology achieves over 99% purity
- Technology reduces energy consumption by approximately 66% compared to conventional methods
- Obtained exclusive sales rights for medical-grade nitrogen-oxygen separation technology
- None.
Insights
The exclusive licensing of 28 multi-regional patents from TCNT significantly strengthens Ainos' intellectual property portfolio in two key areas: AI Nose gas sensing and nitrogen-oxygen separation technology. The latter innovation achieves
The geographic diversity of these patents across major markets (US, EU, China, Japan, Korea, Taiwan, Germany) creates substantial barriers to entry and positions Ainos for strong IP protection. The nitrogen-oxygen separation technology's superior energy efficiency and environmental benefits could provide a significant competitive advantage in the growing medical gas market, while the expanded AI Nose capabilities enhance the company's POCT offerings.
The nitrogen-oxygen separation technology represents a breakthrough in sustainable medical gas production. By reducing energy consumption to approximately 33% of conventional methods while maintaining high purity levels, this innovation addresses both operational costs and environmental impact. The technology's ultra-low carbon emissions align with increasing regulatory pressure and market demand for sustainable healthcare solutions.
This positions Ainos to capitalize on the growing trend toward green medical technologies and could provide first-mover advantages in markets prioritizing environmental compliance. The exclusive licensing rights create a defensible market position in the emerging sustainable medical equipment sector.
Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents
Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices
SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has secured exclusive licensing rights for an additional 28 multi-regional patent assets from its strategic shareholder and product co-developer, Taiwan Carbon Nano Technology Corporation ("TCNT"). These patents encompass innovations in AI Nose gas sensing technology and extend Ainos' technological capabilities with a groundbreaking nitrogen-oxygen separation technology targeting medical applications.
The cutting-edge nitrogen-oxygen separation technology marks a significant leap in generating medical-grade oxygen with exceptional efficiency. It enables a direct extraction of nitrogen and oxygen from air with over
These exclusive licensing rights are part of an amendment to the existing product development agreement between Ainos and TCNT. The patent assets cover a range of advanced technologies including volatile organic compound ("VOC") sensing, POCT, and nitrogen-oxygen separation. They span multiple regions, including China, Japan, Korea, Taiwan, Germany, the European Union, and the U.S., further solidifying Ainos' intellectual property footprint and technological leadership.
Beyond joint technological advancements, the partnership provides Ainos with exclusive sales rights and patent use for the medical-grade nitrogen-oxygen separation technology. This strategically positions the Company to significantly expand its presence in the advanced medical equipment market while empowering a sustainable future.
"These patent assets mark a major milestone for Ainos. They not only enhance our industry-leading AI Nose technology but also introduce transformative, eco-friendly nitrogen-oxygen separation technology. We believe harnessing these intellectual properties will propel our advancements in healthcare technology and highlight our dedication to sustainability." said Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and CEO of Ainos.
For more information, please refer to the Company's current report on Form 8-K filed with the Securities and Exchange Commission on October 22, 2024.
About Ainos, Inc.
Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA). The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.
The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com.
Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc
View the original press release on accesswire.com
FAQ
What new patents did Ainos (AIMD) acquire in October 2024?
How efficient is Ainos (AIMD)'s new nitrogen-oxygen separation technology?
Which regions are covered by Ainos (AIMD)'s new patent portfolio?
